Icure Receives Termination Notice for Donepezil Patch License in Taiwan, Future Revenue Prospects Diminished
Icure announced the termination of its license agreement for Donepezil patch Donecive Patch in Taiwan due to failure to obtain product approval.
The counterparty is A. Menarini Asia-Pacific Holdings Pte. Ltd., and the termination becomes effective on October 3, 2026.
The company received and retains the upfront payment of KRW 1,386,220,000 with no obligation to refund, but loses future milestone payments of EUR 8,000,000 and estimated supply revenue of EUR 39,291,084.
This termination negatively impacts the company's future growth prospects and may exert downward pressure on the stock price.
[AI Summary]The termination of Icure's Donepezil patch license in Taiwan due to regulatory approval failure eliminates significant future revenue streams beyond the already-received upfront. This weakens growth outlook and is a negative catalyst for the stock.
KOSDAQ Filing Information
[Correction of Description] Matters Related to Periodic Disclosure Obligations (Fair Disclosure) - Termination of License Transfer Agreement for Donepezil Patch (Product Name: Donesiv Patch)